These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17579804)

  • 21. Cigarette smoking and progression in multiple sclerosis.
    Koch M; van Harten A; Uyttenboogaart M; De Keyser J
    Neurology; 2007 Oct; 69(15):1515-20. PubMed ID: 17923613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
    Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
    Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early relapses, onset of progression, and late outcome in multiple sclerosis.
    Scalfari A; Neuhaus A; Daumer M; Deluca GC; Muraro PA; Ebers GC
    JAMA Neurol; 2013 Feb; 70(2):214-22. PubMed ID: 23407713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of multiple sclerosis in the Republic of Ireland: A prospective population-based study.
    O'Connell K; Tubridy N; Hutchinson M; McGuigan C
    Mult Scler Relat Disord; 2017 Apr; 13():75-80. PubMed ID: 28427707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.
    Confavreux C; Vukusic S; Adeleine P
    Brain; 2003 Apr; 126(Pt 4):770-82. PubMed ID: 12615637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple sclerosis in Australia: prognostic factors.
    Hammond SR; McLeod JG; Macaskill P; English DR
    J Clin Neurosci; 2000 Jan; 7(1):16-9. PubMed ID: 10847644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis.
    Alroughani R; Ahmed SF; Al-Hashel J
    Pediatr Neurol; 2015 Dec; 53(6):508-12. PubMed ID: 26383244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prevalence of multiple sclerosis in the north-west Italian province of Genoa.
    Solaro C; Allemani C; Messmer Uccelli M; Canevari E; Dagnino N; Pizio R; Regesta G; Tanganelli P; Battaglia MA; Mancardi GL
    J Neurol; 2005 Apr; 252(4):436-40. PubMed ID: 15726261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine, France.
    Gbaguidi B; Guillemin F; Soudant M; Debouverie M; Mathey G; Epstein J
    Sci Rep; 2022 Jan; 12(1):1001. PubMed ID: 35046460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study of multiple sclerosis with early onset.
    Ghezzi A; Pozzilli C; Liguori M; Marrosu MG; Milani N; Milanese C; Simone I; Zaffaroni M
    Mult Scler; 2002 Apr; 8(2):115-8. PubMed ID: 11990867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study.
    Harding KE; Liang K; Cossburn MD; Ingram G; Hirst CL; Pickersgill TP; Te Water Naude J; Wardle M; Ben-Shlomo Y; Robertson NP
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):141-7. PubMed ID: 23154123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics of progressive relapsing multiple sclerosis.
    Tullman MJ; Oshinsky RJ; Lublin FD; Cutter GR
    Mult Scler; 2004 Aug; 10(4):451-4. PubMed ID: 15327045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?
    Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL
    Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and demographical characteristics of primary progressive multiple sclerosis in Isfahan, Iran.
    Maghzi AH; Etemadifar M; Saadatnia M
    Eur J Neurol; 2007 Apr; 14(4):403-7. PubMed ID: 17388988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age at onset determines the occurrence of the progressive phase of multiple sclerosis.
    Stankoff B; Mrejen S; Tourbah A; Fontaine B; Lyon-Caen O; Lubetzki C; Rosenheim M
    Neurology; 2007 Mar; 68(10):779-81. PubMed ID: 17339588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Primary progressive forms of multiple sclerosis: application of the new diagnostic criteria in French].
    De Seze J; Mackowiak A; Stojkovic T; Ferriby D; Hautecoeur P; Vermersch P
    Rev Neurol (Paris); 2002 Mar; 158(3):341-5. PubMed ID: 11976594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.